Clinical Approach to Autoimmune Epilepsy
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Autoimmune epilepsy is a newly emerging area of epilepsy. The concept of “autoimmune” as an etiology has recently been revisited thanks to advances in autoimmune encephalitis and precision medicine with immunotherapies. Autoimmune epilepsy presents with specific clinical manifestations, and various diagnostic approaches including cerebrospinal fluid analysis, neuroimaging, and autoantibody tests are essential for its differential diagnosis. The diagnosis is often indeterminate despite performing a thorough evaluation, and therefore empirical immunotherapy may be applied according to the judgment of the clinician. Autoimmune epilepsy often manifests as new-onset refractory status epilepticus (NORSE). A patient classified as NORSE should receive empirical immunotherapy as soon as possible. On the other hand, a morecautious, stepwise approach is recommended for autoimmune epilepsy that presents with episodic events. The type of autoimmune epilepsy is also an important factor to consider when choosing from among various immunotherapy options. Clinicians should additionally take the characteristics of antiepileptic drugs into account when using them as an adjuvant therapy. This expert opinion discusses the diagnostic and treatment approaches for autoimmune epilepsy from a practical point of view.
Abstract
Autoimmune epilepsy is a newly emerging area of epilepsy. The concept of “autoimmune” as an etiology has recently been revisited thanks to advances in autoimmune encephalitis and precision medicine with immunotherapies. Autoimmune epilepsy presents with specific clinical manifestations, and various diagnostic approaches including cerebrospinal fluid analysis, neuroimaging, and autoantibody tests are essential for its differential diagnosis. The diagnosis is often indeterminate despite performing a thorough evaluation, and therefore empirical immunotherapy may be applied according to the judgment of the clinician. Autoimmune epilepsy often manifests as new-onset refractory status epilepticus (NORSE). A patient classified as NORSE should receive empirical immunotherapy as soon as possible. On the other hand, a morecautious, stepwise approach is recommended for autoimmune epilepsy that presents with episodic events. The type of autoimmune epilepsy is also an important factor to consider when choosing from among various immunotherapy options. Clinicians should additionally take the characteristics of antiepileptic drugs into account when using them as an adjuvant therapy. This expert opinion discusses the diagnostic and treatment approaches for autoimmune epilepsy from a practical point of view.
참고문헌 (60)
- Scheffer IE, "ILAE classification of the epilepsies : position paper of the ILAE Commission for Classification and Terminology", Epilepsia, 58, pp.512~521 (2017)
- Prüss H, "N-methyl-D-aspartate receptor antibodies in herpes simplex encephalitis", Ann Neurol, 72, pp.902~911 (2012)
- Leypoldt F, "Herpes simplex virus-1 encephalitis can trigger anti-NMDA receptor encephalitis : case report", Neurology, 81, pp.1637~1639 (2013)
- Hirsch LJ, "Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions", Epilepsia, 59, pp.739~744 (2018)
- Graus F, "A clinical approach to diagnosis of autoimmune encephalitis", Lancet Neurol, 15, pp.391~404 (2016)
- Irani SR, "Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis", Ann Neurol, 69, pp.892~900 (2011)
- Spatola M, "Investigations in GABAA receptor antibody-associated encephalitis", Neurology, 88, pp.1012~1020 (2017)
- Eric Lancaster, "Te Diagnosis and Treatment of Autoimmune Encephalitis", Journal of Clinical Neurology, 12(1), pp.1~13 (2016), 대한신경과학회[DOI]
- Titulaer MJ, "Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis : an observational cohort study", Lancet Neurol, 12, pp.157~165 (2013)
- Dalmau J, "Antibody-mediated encephalitis", N Engl J Med, 378, pp.840~851 (2018)
- Gaspard N, "New-onset refractory status epilepticus : etiology, clinical features, and outcome", Neurology, 85, pp.1604~1613 (2015)
- Lee WJ, "Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort", Neurology, 86, pp.1683~1691 (2016)
- Blinder T, "Cerebrospinal fluid findings in patients with autoimmune encephalitis-a systematic analysis", Front Neurol, 10, pp.804~ (2019)
- Hocker S, "Progressive brain atrophy in super-refractory status epilepticus", JAMA Neurol, 73, pp.1201~1207 (2016)
- Iizuka T, "Reversible brain atrophy in anti-NMDA receptor encephalitis : a long-term observational study", J Neurol, 257, pp.1686~1691 (2010)
- Finke C, "Evaluation of cognitive deficits and structural hippocampal damage in encephalitis with leucine-rich, glioma-inactivated 1 antibodies", JAMA Neurol, 74, pp.50~59 (2017)
- Jang Y, "LGI1 expression and human brain asymmetry : insights from patients with LGI1-antibody encephalitis", J Neuroinflammation, 15, pp.279~ (2018)
- Yoo RE, "Identification of cerebral perfusion using arterial spin labeling in patients with seizures in acute settings", PLoS One, 12, pp.e0173538~ (2017)
- Schmitt SE, "Extreme delta brush : a unique EEG pattern in adults with anti-NMDA receptor encephalitis", Neurology, 79, pp.1094~1100 (2012)
- Irani SR, "Faciobrachial dystonic seizures : the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype", Brain, 136, pp.3151~3162 (2013)
- Granerod J, "Causes of encephalitis and differences in their clinical presentations in England : a multicentre, population-based prospective study", Lancet Infect Dis, 10, pp.835~844 (2010)
- Dubey D, "Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis", Ann Neurol, 83, pp.166~177 (2018)
- Jang Y, "Cerebral autoinflammatory disease treated with anakinra", Ann Clin Transl Neurol, 5, pp.1428~1433 (2018)
- Lee WJ, "Tocilizumab in autoimmune encephalitis refractory to rituximab : an institutional cohort study", Neurotherapeutics, 13, pp.824~832 (2016)
- Shin YW, "Bortezomib treatment for severe refractory anti-NMDA receptor encephalitis", Ann Clin Transl Neurol, 5, pp.598~605 (2018)
- Li J, "Plasma exchange in cryptogenic new onset refractory status epilepticus", Seizure, 22, pp.70~73 (2013)
- Gall CR, "Five cases of new onset refractory status epilepticus (NORSE) syndrome: outcomes with early immunotherapy", Seizure, 22, pp.217~220 (2013)
- Lopinto-Khoury C, "Autoimmune status epilepticus", Curr Treat Options Neurol, 15, pp.545~556 (2013)
- Gaspard N, "New-onset refractory status epilepticus(NORSE)and febrile infection-related epilepsy syndrome(FIRES) : state of the art and perspectives", Epilepsia, 59, pp.745~752 (2018)
- Kenney-Jung DL, "Febrile infection-related epilepsy syndrome treated with anakinra", Ann Neurol, 80, pp.939~945 (2016)
- Sakuma H, "Intrathecal overproduction of proinflammatory cytokines and chemokines in febrile infection-related refractory status epilepticus", J Neurol Neurosurg Psychiatry, 86, pp.820~822 (2015)
- Jun JS, "Tocilizumab treatment for new onset refractory status epilepticus", Ann Neurol, 84, pp.940~945 (2018)
- Iro MA, "Intravenous immunoglobulin for the treatment of childhood encephalitis", Cochrane Database Syst Rev (2017)
- Byun JI, "Prevalence of antineuronal antibodies in patients with encephalopathy of unknown etiology : data from a nationwide registry in Korea", J Neuroimmunol, 293, pp.34~38 (2016)
- Liu X, "Seizure outcomes in patients with anti-NMDAR encephalitis : a follow-up study", Epilepsia, 58, pp.2104~2111 (2017)
- de Bruijn MAAM, "Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis", Neurology, 92, pp.e2185~e2196 (2019)
- Slade JD, "Prednisone-induced alterations of circulating human lymphocyte subsets", J Lab Clin Med, 101, pp.479~487 (1983)
- Lahood N, "Antibody levels and response to pneumococcal vaccine in steroid-dependent asthma", Ann Allergy, 70, pp.289~294 (1993)
- 선우준상, "자가면역 뇌염에서 코르티코스테로이드 치료", Journal of Neurocritical Care, 10(2), pp.60~68 (2017), 대한신경집중치료학회[DOI]
- Lünemann JD, "Efficacy of intravenous immunoglobulin in neurological diseases", Neurotherapeutics, 13, pp.34~46 (2016)
- Somers EC, "Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus", Arthritis Rheum, 52, pp.2761~2767 (2005)
- van Sonderen A, "Anti-LGI1 encephalitis : clinical syndrome and longterm follow-up", Neurology, 87, pp.1449~1456 (2016)
- Thompson J, "The importance of early immunotherapy in patients with faciobrachial dystonic seizures", Brain, 141, pp.348~356 (2018)
- Gultekin SH, "Paraneoplastic limbic encephalitis : neurological symptoms, immunological findings and tumour association in 50 patients", Brain, 123, pp.1481~1494 (2000)
- Brophy GM, "Guidelines for the evaluation and management of status epilepticus", Neurocrit Care, 17, pp.3~23 (2012)
- Shin YW, "Increased adverse events associated with antiepileptic drugs in anti-leucine-rich glioma-inactivated protein 1 encephalitis", Epilepsia 2018;59 Suppl, 59(Suppl 2), pp.108~112 (2018)
- Vandevyver S, "New insights into the anti-inflammatory mechanisms of glucocorticoids : an emerging role for glucocorticoid-receptor-mediated transactivation", Endocrinology, 154, pp.993~1007 (2013)
- Mahata B, "Single-cell RNA sequencing reveals T helper cells synthesizing steroids de novo to contribute to immune homeostasis", Cell Rep, 7, pp.1130~1142 (2014)
- Schwab I, "Intravenous immunoglobulin therapy : how does IgG modulate the immune system?", Nat Rev Immunol, 13, pp.176~189 (2013)
- Jang Y, "High albumin level is a predictor of favorable response to immunotherapy in autoimmune encephalitis", Sci Rep, 8, pp.1012~ (2018)
- Shin YW, "Treatment strategies for autoimmune encephalitis", Ther Adv Neurol Disord, 11, pp.1756285617722347~ (2017)
- Johnson PW, "Rituximab : mechanisms and applications", Br J Cancer, 85, pp.1619~1623 (2001)
- Martin ST, "Hepatitis B reactivation and rituximab : a new boxed warning and considerations for solid organ transplantation", Am J Transplant, 14, pp.788~796 (2014)
- Shetty A, "Tocilizumab in the treatment of rheumatoid arthritis and beyond", Drug Des Devel Ther, 8, pp.349~364 (2014)
- Emadi A, "Cyclophosphamide and cancer : golden anniversary", Nat Rev Clin Oncol, 6, pp.638~647 (2009)
- Mertens M, "Anakinra for rheumatoid arthritis : a systematic review", J Rheumatol, 36, pp.1118~1125 (2009)
- Meister S, "Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition", Cancer Res, 67, pp.1783~1792 (2007)
- Johnson PJ, "Azathioprine for long-term maintenance of remission in autoimmune hepatitis", N Engl J Med, 333, pp.958~963 (1995)
- Iaccarino L, "Mycophenolate mofetil : what is its place in the treatment of autoimmune rheumatic diseases?", Autoimmun Rev, 6, pp.190~195 (2007)
- Ginzler EM, "Mycophenolate mofetil in lupus nephritis", Lupus, 14, pp.59~64 (2005)